Doxorubicin Hydrochloride Liposome Injection, Suspension, Liposomal
Product Images NDC 25021-263

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride Liposome (NDC 25021-263). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Dox0e 0000 01)

Chemical structure of doxorubicin hydrochloride displayed as a 2D molecular diagram, with labeled atoms and bonds illustrating its complex arrangement including hydroxyl, methoxy, and amino groups.*

FDA Label Image

Mpeg-dspe Structural Formula (Dox0e 0000 02)

Chemical structure diagram illustrating a molecular compound with polymeric segments, ester and amide linkages, phosphate groups, and long hydrocarbon chains. The image includes a notation indicating n is approximately 45, suggesting polymer repeat units. This structure is associated with the active ingredient Doxorubicin Hydrochloride in liposomal formulation.*

FDA Label Image

Hspc Structural Formula (Dox0e 0000 03)

Chemical structure diagram depicting the molecular formula of Doxorubicin Hydrochloride Liposome. The diagram includes various chemical bonds and atomic groups, illustrating the composition of the liposomal formulation variant with indicated m and n values as 14 or 16.*

FDA Label Image

Representation Of A Pegylated Liposome (Dox0e 0000 04)

An illustration diagram showing the structure of a liposomal particle for Doxorubicin Hydrochloride. It labels the MPEG-DSPE coating on the outer surface, the liposomal bilayer beneath it, and the aqueous core containing entrapped doxorubicin hydrochloride in the center.*

FDA Label Image

Figure 1 (Dox0e 0000 05)

This is a Kaplan-Meier survival curve showing the percent of subjects progression-free over time in months for treatments with Doxorubicin Hydrochloride plus Bortezomib versus Bortezomib alone. The graph includes p-value, hazard ratio (HR), and number of subjects at risk for each treatment group over time, with censored data points indicated.*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Dox0e 0000 06)

Label for Doxorubicin Hydrochloride Liposome Injection 20 mg per 10 mL (2 mg per mL) by Sagent Pharmaceuticals. The label indicates a liposomal formulation for intravenous infusion only after dilution. The vial is single-dose, sterile, preservative-free, and nonpyrogenic, with storage instructions and a caution that it is a cytotoxic agent.*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Dox0e 0000 07)

Label for Doxorubicin Hydrochloride Liposome Injection 50 mg per 25 mL (2 mg per mL) in a single-dose vial. The packaging states it is a liposomal formulation for intravenous infusion only after dilution. The label includes cautionary notes about it being a cytotoxic agent and not substitutable for doxorubicin hydrochloride. Manufactured for Sagent Pharmaceuticals, Schaumburg, IL, made in China, with storage instructions included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.